Edap Tms EBIT Margin
The EBIT Margin (Operating Margin) of Edap Tms (EDAP) as of Jul 26, 2026 is -40.25 %. In the previous year, EBIT Margin (Operating Margin) was -32.03 % — a change of 25.67% (lower).
Get this data via API
Financial Data API
EBIT Margin
-40.25 %
YoY
25.67%
Last updated:
EBIT Margin (Operating Margin) of Edap Tms is 2026 -40.25 % . EBIT Margin (Operating Margin) of Edap Tms was 2025 -32.03 % . It decreases by 25.67% lower compared to the previous year.
For Edap Tms, the operating (EBIT) margin of -40.2% is down versus -3.7% a few years ago.
Access this data via the Eulerpool API
Edap Tms Stock analysis
What does Edap Tms do? Edap Tms SA is a French company specialized in the development and marketing of medical devices. The company was founded in 1979 and has its headquarters in Vaulx-en-Velin, France. With over 300 employees, Edap Tms SA operates worldwide and has branches in the USA, Asia, and Europe.
The company's business model is based on the development of non-invasive medical devices, particularly HIFU (High-Intensity Focused Ultrasound) devices. With its technology, the company has developed a revolutionary new procedure for tumor treatment that can replace traditional radiation therapy. HIFU offers a gentler and more precise alternative for tumor treatment without damaging the surrounding tissue.
Edap Tms SA offers its products and services in four main business areas:
1. HIFU systems for the treatment of prostate cancer: Edap Tms SA has developed a HIFU system capable of treating prostate cancer without invasive procedures. The system uses a special ultrasound probe inserted into the rectum to locate the tumor and direct targeted sound waves at the tumor, destroying cancer cells.
2. HIFU systems for the treatment of kidney cancer: Edap Tms SA has also developed a HIFU system capable of treating kidney cancer tumors. It works similarly to the prostate cancer system, effectively destroying the tumor through targeted sound waves.
3. Mobile HIFU devices: Edap Tms SA has developed mobile HIFU devices suitable for use in hospitals and clinics. These devices can be quickly and easily transported from room to room, allowing medical professionals to perform HIFU treatments without the need for additional equipment.
4. Bladder cancer treatment technology: Edap Tms SA has also developed technology used in the treatment of bladder cancer. The system also utilizes HIFU technology to destroy tumor cells, but it is introduced through the urethra and focuses on the tumor in the bladder.
Edap Tms SA is a global leader in the development and marketing of HIFU systems. The company aims to improve cancer treatment and provide patients with a more effective and gentler alternative to traditional radiation therapy. With a wide range of products suitable for various types of cancer and a strong presence in the USA, Europe, and Asia, Edap Tms SA is a highly regarded brand in the medical device field.
Overall, Edap Tms SA is a company with a rich history that focuses on innovative technologies and continuously strives to improve the lives of cancer patients. With its HIFU portfolio and strong market presence, the company is on track to achieve its goals and solidify its position as one of the leading providers of medical devices worldwide. Edap Tms is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Edap Tms stock
EBIT Margin (Operating Margin) of Edap Tms is -40.25 % in 2026.
Access this data via the Eulerpool API
Margins — Edap Tms
All Key Metrics — Edap Tms
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth